Selecta Biosciences Inc

NASDAQ:SELB   12:14:29 PM EDT
2.33
+0.08 (+3.80%)
Products, Regulatory

Selecta Biosciences And SOBI Announce Completion Of Enrollment In Dissolve Phase 3 Study Evaluating Sel-212 For Chronic Refractory Gout

Published: 12/01/2021 13:29 GMT
Selecta Biosciences Inc (SELB) - Selecta Biosciences and Sobi Announce Completion of Enrollment in Dissolve Phase 3 Study Evaluating Sel-212 for Chronic Refractory Gout.
Selecta Biosciences Inc - Dissolve Program on Track With 12-month Study Fully Enrolled.
Selecta Biosciences Inc - Dissolve Ii on Track for Full Enrollment in Early 2022.
Selecta Biosciences Inc - Top-line Data From Phase 3 Dissolve Program Expected in H2 2022.